Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL2939655

COC[C@H]1CCCN1C(=O)c1ccc(C)nc1NCc1ccco1.O=C(O)C(F)(F)F

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
REN P00797 3/20 0.70
LRRK2 Q5S007 2/20 0.42
HPGD P15428 3/20 0.38
KDM4E B2RXH2 3/20 0.38
HSD17B10 Q99714 2/20 0.38
CACNA1B Q00975 1/20 0.37
APBA1 Q02410 1/20 0.37
KCNK3 O14649 2/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
ALDH1A1 P00352 4/20 0.36
LMNA P02545 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
GAA P10253 2/20 0.36
TSHR P16473 2/20 0.36
HTT P42858 1/20 0.36
ALOX15 P16050 1/20 0.36
MAPK1 P28482 1/20 0.36
HRH4 Q9H3N8 1/20 0.36
SOS1 Q07889 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12991017 0.94 REN (0.77) RENLRRK2HPGDKDM4EHSD17B10
SCHEMBL2903500 0.82 REN (1.00) RENHPGDKDM4EHSD17B10NPC1
SCHEMBL2912713 0.79 REN (0.67) RENHPGDKDM4EHSD17B10ALDH1A1
Trifluoroacetic Acid SCHEMBL2898732 0.78 REN (0.54) RENHPGDKDM4EHSD17B10LMNA
Trifluoroacetic Acid SCHEMBL2897418 0.77 REN (0.53) RENHPGDCACNA1BAPBA1
Trifluoroacetic Acid SCHEMBL2902708 0.76 REN (0.68) RENHPGDNPC1RAB9AALDH1A1
Trifluoroacetic Acid SCHEMBL2897383 0.76 REN (0.67) RENHPGDKDM4EHSD17B10ALDH1A1
Trifluoroacetic Acid SCHEMBL2902475 0.75 REN (0.51) RENALDH1A1
Trifluoroacetic Acid SCHEMBL2901344 0.75 REN (0.51) RENHPGDKDM4EHSD17B10CACNA1B
Trifluoroacetic Acid SCHEMBL2902360 0.74 REN (0.50) RENCACNA1BAPBA1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2202228-B1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL (JP) 2014-12-10 EP disclosed
US-8329691-B2 Amide compounds and use of the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-11 US disclosed
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-23 US disclosed
EP-2202228-A1 AMIDE COMPOUNDS AND USE OF THE SAME Takeda Pharmaceutical Company Limited (JP) 2010-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME REN, ACE, AGT REN 1/4885LRRK2 4069/4885HPGD 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.